Clinical Relevance
The present study supports incorporation of prucalopride in
colon-specific drug delivery systems to be used as a prokinetic for
treating hypomotility disorders. Newer drug delivery systems targeting
the colon use polysaccharide coatings that can be degraded only by the
microorganisms existing in the colon which results in increased delivery
success. With the advancement of nanotechnology, various forms of
nanoparticle formulations for colon delivery have also been investigated
(53) which could replace other types of colon-specific delivery systems
in the future. This can be especially beneficial for high-risk
populations such as the elderly and children.